DSCO is next IXGN cheapest Biotech on NASDAQ. $3 soon: -Tiny 21 Million float.
-$27 million cash or $1.1 per share.
-DSCO has resolved manufacturing issues and is ready to file a New Drug Application in a vew months for a drug with a potential $1.8 billion market. Back out the cash, the market is valuing DSCO at $30 million, the cheapest valuation by miles for any stock with pending drug application.
- The sector is hot and will stay on fire until ASCO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.